• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Buyouts

Advent to take Mediq private for €775m

  • Anneken Tappe
  • 24 September 2012
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Advent International has announced plans to delist Dutch pharma company Mediq from the Euronext Amsterdam, valuing the company at €775m.

The acquisition will be made through AI Garden BV, wholly owned by Advent. The GP is offering €13.25 (cum dividend) in cash for all issued and outstanding Mediq shares. This represents a 53% premium on last week's closing share price and a 47% premium on the three-month average.

Existing Mediq shareholders Templeton Investment Counsel and Silchester International Investors, which own a combined share of 20.2%, will accept and support the offer. Mediq's board also approved and recommended Advent's offer.

Mediq

  • DEAL:

    Take-private

  • VALUE:

    €775m

  • LOCATION:

    Utrecht

  • SECTOR:

    Medical supplies

  • FOUNDED:

    1899

  • TURNOVER:

    €2.7bn

  • STAFF:

    8,300

The parties involved are currently seeking all necessary approvals and clearances, and are planning to go ahead with the process in Q4 2012.

Following the transaction, Advent will follow a buy-and-build strategy for Mediq, focusing on its direct and institutional distribution channel, in order to strengthen its position in the Dutch pharma market.

Advent plans to leave Mediq's two-tier board structure in place; the current management board will remain unchanged following the transaction. The GP announced there would be no redundancies as a direct consequence of the takeover.

Company
Mediq is a Dutch pharmaceuticals, medical devices and care services company headquartered in Utrecht. Founded in 1899, the business delivers products and services directly to individuals, via hospitals, nursing homes and other healthcare institutions.

In 2011, Mediq recorded sales of €2.7bn. It is currently listed on the Euronext Amsterdam.

People
Tom Allen and Bram Grimmelt led the deal on behalf of Advent. Sjoerd van Keulen chairs Mediq's supervisory board and Marc van Gelder is the company's CEO.

Advisers
Equity – Deutsche Bank (M&A); Rabobank (M&A); BNP Paribas (M&A); Marlborough Partners (Debt advisory); Freshfields Burckhauser Deringer (Legal).
Company – ING Bank (M&A); Allen & Overy (Legal).
Supervisory Board – ABN Amro (M&A).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Buyouts
  • Benelux
  • Now researching
  • Healthcare
  • Take Private
  • ABN Amro
  • Deutsche Bank
  • Advent International
  • Netherlands
  • Euronext
  • BNP Paribas
  • Allen & Overy
  • Freshfields Bruckhaus Deringer
  • Marlborough Partners
  • Rabobank
  • ING

More on Buyouts

Clinical trials and biotechnology
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
EMEA Public to Private M&A
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023
HR software solutions providers
Main Capital’s Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023
Ice cream
Exponent divests ‘significant' stake in Meadow to Canadian investor

Since 2018, GP has diversified food ingredients company's focus beyond commodity dairy

  • Exits
  • 22 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013